Jorge Riera Knorrenschild

Mutation-based, neoadjuvant treatment for advanced anaplastic thyroid carcinoma

Sabine Wächter, Detlef K. Bartsch, Jorge Riera Knorrenschild, Anika Pehl et autres

Introduction: The prognosis of anaplastic thyroid carcinoma (ATC) remains poor. Mutation-based targeted therapies and immune checkpoint inhibitors (ICI) have gained increasing importance in the treatment of advanced tumor stages. This study aimed to investigate whether mutation-based neoadjuvant therapy can convert an initially …

de (code pays fourni par la source)

Barriers and facilitators for the utilisation of psycho-oncological services in German hospitals as perceived by patients and healthcare professionals: a mixed-methods study

Liv Betker, Koral Buch, Pia Berlin, Anna J. Pedrosa Carrasco et autres

BACKGROUND: Psycho-oncological services (POS) are an integral and widely recommended part of comprehensive cancer care. However, their utilisation appears to fall short of the perceived need. This study aimed to explore barriers and facilitators for the uptake of POS in the context …

de (code pays fourni par la source)

407P Immune composition-based efficacy assessment of first-line immune-chemotherapy combinations in gastroesophageal cancer: Subgroup analysis of the phase II IKF-AIO-STO-0417 / moonlight trial

Michael Masetti, M. Ángela Nieto, S. Lorenzen, S-E. Al-Batran et autres

de (code pays fourni par la source)

1450P Pembrolizumab and olaparib in advanced HER2 negative esophagogastric adenocarcinoma (EGA): Biomarker results of the phase II AIO IKF-038/POLESTAR trial

Georg Martin Haag, Thorsten Oliver Goetze, P. Thuss-Patience, Jorge Riera Knorrenschild et autres

de (code pays fourni par la source)

873P Nivolumab (NIVO) in the first-line (1L) or second-line (2L) and later (2L+) settings in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Updated results from the German non-interventional study (NIS), HANNA

A. Dietz, D.A. Hahn, C. Langer, B. Kubuschok et autres

de, at, ee (code pays fourni par la source)

LBA59 Modified FOLFOX plus/minus nivolumab and ipilimumab vs FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Final results of the IKF-AIO-Moonlight trial

Sylvie Lorenzen, Thorsten Oliver Goetze, Peter Thuss‐Patience, Jorge Riera Knorrenschild et autres

de (code pays fourni par la source)

Collaborative advance care planning in palliative care: a randomised controlled trial

Carola Seifart, Martin C. Koch, Svenja Herzog, Nico Leppin et autres

OBJECTIVE: An effective tool for establishing concordant end-of-life (EOL) care in patients with cancer is advance care planning (ACP). However, various barriers, including psychological obstacles, hamper the access to ACP. Therefore, a new conceptual model combining a psycho-oncological approach with structured ACP …

de (code pays fourni par la source)

424P Pembrolizumab and olaparib in advanced HER2-negative esophagogastric adenocarcinoma: First results of the phase II AIO IKF-038/POLESTAR trial

Georg Martin Haag, Thorsten Oliver Goetze, P. Thuss-Patience, Jorge Riera Knorrenschild et autres

de (code pays fourni par la source)

Efficacy of ramucirumab combination chemotherapy as second‐line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first‐line therapy

Michael Masetti, Salah‐Eddin Al‐Batran, Thorsten Oliver Goetze, Peter Thuss‐Patience et autres

FOLFOX plus nivolumab represents a standard of care for first-line therapy of advanced gastroesophageal cancer (aGEC) with positive PD-L1 expression. The efficacy of second-line VEGFR-2 inhibition with ramucirumab (RAM) plus chemotherapy after progression to immunochemotherapy remains unclear. Medical records of patients with …

de (code pays fourni par la source)

Difficulties of Cancer Patients’ Relatives in End-of-Life Discussions: Validation of a Questionnaire

Liv Betker, Alina Senßfelder, Jorge Riera Knorrenschild, Christian Volberg et autres

CONTEXT: Despite the potential benefits and the desire for end-of-life communication, it rarely occurs in the familial context. Relatives play a significant role in the communication process; thus, it is crucial to understand the difficulties that they face. OBJECTIVES: To develop and …

de (code pays fourni par la source)

Difficulty in End-of-Life Discussions--Family Inventory; Version for Relatives

Liv Betker, Alina Senßfelder, Jorge Riera Knorrenschild, Christian Volberg et autres

Cancer advance care planning: development of a screening tool

Pia Berlin, Lena Göggelmann, Svenja Herzog, Anna J. Pedrosa Carrasco et autres

Objectives Advance care discussions are a useful communication tools for medical preferences and beneficial for shared decision-making processes in hospital settings. The present study developed the first screening tool for need for advance care planning (ACP). Methods In phase 1 (n=92), items …

de (code pays fourni par la source)